(From right) Kim Jae-soon, vice president of Chong Kun Dang pharmaceutical; Dr. Debra Peattie; Luciano Santolani, Apellos Bioscience CTO; Kim Sun-hong, head of research planning at Chong Kun Dang pharmaceutical; and Kim Ho-won, head of CKD USA, pose for a commemorative photo in Boston, United States, on the 20th (local time). /Courtesy of Chong Kun Dang pharmaceutical

Chong Kun Dang pharmaceutical said on the 21st that it will support technology discovery by bio startups. It recently held an event in Boston and awarded a "golden ticket" to the bio corporations Aphelos Bioscience.

This is an event that Chong Kun Dang pharmaceutical and the U.S. nonprofit LabCentral are conducting for open innovation. LabCentral has so far facilitated $218 in investment attraction for 344 bio corporations. corporations can move into LabCentral to discover technologies and build a global network.

Aphelos Bioscience was founded in 2024. It is developing treatments for autoimmune diseases based on artificial intelligence (AI). It holds technologies related to proteins and T-cell biology.

About 50 bio startups applied to this event. Harvard University Professor Park Jin-mo and Dr. Debra Peattie served as judges. A Chong Kun Dang pharmaceutical official said, "We will create tangible collaboration outcomes, including joint research and development."

※ This article has been translated by AI. Share your feedback here.